Does Wegovy Increase Resting Heart Rate?

What the STEP trials actually recorded on heart rate

The STEP 1 trial (68 weeks, semaglutide 2.4 mg versus placebo in adults living with obesity) is the most cited reference point here. Across the STEP programme, participants taking semaglutide experienced a mean increase in resting heart rate of approximately 1 to 4 beats per minute compared with placebo. That figure is consistent across the studies, which is why regulators and prescribers treat it as a genuine pharmacological effect rather than noise. You can read the published STEP 1 data in the New England Journal of Medicine.

The mechanism is thought to relate to GLP-1 receptor activity in the cardiac conduction system — the same pathway that slows gastric emptying and reduces appetite also has some effect on the heart's pacing. It is not unique to semaglutide; similar small rises appear with other GLP-1 receptor agonists.

For most participants, the rise sat well within the normal heart rate range and did not produce symptoms. It is worth noting that body weight loss itself generally lowers resting heart rate over time, so the two effects can partially offset each other as treatment progresses. The net cardiovascular picture for eligible patients is considered favourable by regulators, but the heart rate signal is real and documented.

When a raised resting heart rate matters more

A jump of two or three beats per minute is unlikely to be felt by someone with a healthy cardiovascular system. Where it deserves more attention is in people who already live with tachycardia, atrial fibrillation, or certain other arrhythmias, or those taking medicines that also affect heart rate. In those cases, the starting question is not whether semaglutide raises heart rate in principle, but what the individual baseline looks like and what other factors are in play.

The NHS medicines page for semaglutide lists heart-rate changes among the effects to be aware of, alongside the more commonly discussed gastrointestinal side effects. If you notice a persistent or uncomfortable change in your pulse after starting or after a dose increase, that is worth reporting to your prescriber rather than waiting for your next scheduled review.

The MHRA's Yellow Card scheme is the right route for anything that feels unexpected or serious. Reports from real patients are how post-market safety signals are built, the scheme is open to patients, not just clinicians.

How this shapes the prescribing assessment at nume

Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not software processing a form. Heart rate and cardiovascular history are part of what they consider. If your baseline pulse is already at the higher end, or if you have a cardiac condition listed in your medical history, the prescriber will weigh that before approving any treatment.

This is also why dose titration exists as a process rather than a single jump: starting at 0.25 mg and moving upward in staged steps, including through the 2.0 mg maintenance dose, means any physiological changes (including shifts in heart rate) can be noticed and managed rather than arriving all at once. Our clinical team's approach to this is described on the prescribers page.

People who have experienced a noticeable heart rate increase on Wegovy sometimes ask whether switching to a different dose or treatment would help. That is a clinical conversation. If you are already on Wegovy and noticing pulse changes, contact our aftercare team rather than adjusting anything yourself.

Putting the finding in proportion

A one-to-four bpm rise in resting heart rate is a legitimate pharmacological effect, not a reason to dismiss the medicine, and not a reason to dismiss the signal either. It sits alongside the well-documented cardiovascular benefits recorded in the SELECT trial, where semaglutide reduced major adverse cardiovascular events in high-risk patients. Both facts can be true at once.

For the typical person starting Wegovy for weight management, the heart-rate change is modest, does not usually cause symptoms, and is monitored as part of ongoing clinical care. The full Wegovy treatment overview covers the broader side effect picture if you want to read further. Anyone curious about whether their personal circumstances make them a suitable candidate can get a clearer picture through a structured clinical assessment, there is a fuller look at semaglutide and what causes heart rate changes on Wegovy if you want to go deeper on the mechanism before booking in.

Wegovy is a prescription-only medicine. If you'd like a personalised assessment from our prescribers, start your free consultation and they will review your full health picture the same day.